vs
CACI INTERNATIONAL INC（CACI）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
CACI INTERNATIONAL INC的季度营收约是瑞思迈的1.6倍（$2.2B vs $1.4B），瑞思迈净利率更高（27.6% vs 5.6%，领先22.0%），瑞思迈同比增速更快（11.0% vs 5.7%），瑞思迈自由现金流更多（$311.2M vs $138.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs 7.0%）
CACI国际公司是总部位于美国的跨国专业服务与信息技术企业，主要为国防、情报、民用政府部门及部分私营领域客户提供定制技术解决方案、网络安全服务、数据分析支持与关键任务运营保障服务。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
CACI vs RMD — 直观对比
营收规模更大
CACI
是对方的1.6倍
$1.4B
营收增速更快
RMD
高出5.2%
5.7%
净利率更高
RMD
高出22.0%
5.6%
自由现金流更多
RMD
多$173.1M
$138.2M
两年增速更快
RMD
近两年复合增速
7.0%
损益表 — Q2 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.2B | $1.4B |
| 净利润 | $123.9M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 9.3% | 34.6% |
| 净利率 | 5.6% | 27.6% |
| 营收同比 | 5.7% | 11.0% |
| 净利润同比 | 12.7% | 13.9% |
| 每股收益（稀释后） | $5.59 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CACIRMD
| Q4 25 | $2.2B | $1.4B | ||
| Q3 25 | $2.3B | $1.3B | ||
| Q2 25 | $2.3B | $1.3B | ||
| Q1 25 | $2.2B | $1.3B | ||
| Q4 24 | $2.1B | $1.3B | ||
| Q3 24 | $2.1B | $1.2B | ||
| Q2 24 | $2.0B | $1.2B | ||
| Q1 24 | $1.9B | $1.2B |
净利润CACIRMD
| Q4 25 | $123.9M | $392.6M | ||
| Q3 25 | $124.8M | $348.5M | ||
| Q2 25 | $157.9M | $379.7M | ||
| Q1 25 | $111.9M | $365.0M | ||
| Q4 24 | $109.9M | $344.6M | ||
| Q3 24 | $120.2M | $311.4M | ||
| Q2 24 | $134.7M | $292.2M | ||
| Q1 24 | $115.3M | $300.5M |
毛利率CACIRMD
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 57.9% |
营业利润率CACIRMD
| Q4 25 | 9.3% | 34.6% | ||
| Q3 25 | 9.3% | 33.4% | ||
| Q2 25 | 9.0% | 33.7% | ||
| Q1 25 | 9.1% | 33.0% | ||
| Q4 24 | 8.6% | 32.5% | ||
| Q3 24 | 8.7% | 31.6% | ||
| Q2 24 | 9.7% | 31.2% | ||
| Q1 24 | 9.4% | 31.3% |
净利率CACIRMD
| Q4 25 | 5.6% | 27.6% | ||
| Q3 25 | 5.5% | 26.1% | ||
| Q2 25 | 6.9% | 28.2% | ||
| Q1 25 | 5.2% | 28.3% | ||
| Q4 24 | 5.2% | 26.9% | ||
| Q3 24 | 5.8% | 25.4% | ||
| Q2 24 | 6.6% | 23.9% | ||
| Q1 24 | 6.0% | 25.1% |
每股收益（稀释后）CACIRMD
| Q4 25 | $5.59 | $2.68 | ||
| Q3 25 | $5.63 | $2.37 | ||
| Q2 25 | $7.11 | $2.58 | ||
| Q1 25 | $5.00 | $2.48 | ||
| Q4 24 | $4.88 | $2.34 | ||
| Q3 24 | $5.33 | $2.11 | ||
| Q2 24 | $5.97 | $1.97 | ||
| Q1 24 | $5.13 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $423.0M | $1.4B |
| 总债务越低越好 | $3.0B | $403.9M |
| 股东权益账面价值 | $4.1B | $6.3B |
| 总资产 | $8.9B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.72× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资CACIRMD
| Q4 25 | $423.0M | $1.4B | ||
| Q3 25 | $133.0M | $1.4B | ||
| Q2 25 | $106.2M | $1.2B | ||
| Q1 25 | $223.9M | $932.7M | ||
| Q4 24 | $175.7M | $521.9M | ||
| Q3 24 | $440.7M | $426.4M | ||
| Q2 24 | $134.0M | $238.4M | ||
| Q1 24 | $159.2M | $237.9M |
总债务CACIRMD
| Q4 25 | $3.0B | $403.9M | ||
| Q3 25 | $2.8B | $408.7M | ||
| Q2 25 | $2.9B | $658.4M | ||
| Q1 25 | $3.1B | $663.1M | ||
| Q4 24 | $3.1B | $662.9M | ||
| Q3 24 | $1.8B | $667.6M | ||
| Q2 24 | $1.5B | $697.3M | ||
| Q1 24 | $1.7B | $997.0M |
股东权益CACIRMD
| Q4 25 | $4.1B | $6.3B | ||
| Q3 25 | $4.0B | $6.1B | ||
| Q2 25 | $3.9B | $6.0B | ||
| Q1 25 | $3.7B | $5.5B | ||
| Q4 24 | $3.7B | $5.3B | ||
| Q3 24 | $3.7B | $5.2B | ||
| Q2 24 | $3.5B | $4.9B | ||
| Q1 24 | $3.4B | $4.6B |
总资产CACIRMD
| Q4 25 | $8.9B | $8.5B | ||
| Q3 25 | $8.7B | $8.3B | ||
| Q2 25 | $8.6B | $8.2B | ||
| Q1 25 | $8.6B | $7.6B | ||
| Q4 24 | $8.5B | $7.1B | ||
| Q3 24 | $7.2B | $7.2B | ||
| Q2 24 | $6.8B | $6.9B | ||
| Q1 24 | $6.8B | $6.8B |
负债/权益比CACIRMD
| Q4 25 | 0.72× | 0.06× | ||
| Q3 25 | 0.69× | 0.07× | ||
| Q2 25 | 0.75× | 0.11× | ||
| Q1 25 | 0.84× | 0.12× | ||
| Q4 24 | 0.82× | 0.13× | ||
| Q3 24 | 0.50× | 0.13× | ||
| Q2 24 | 0.44× | 0.14× | ||
| Q1 24 | 0.50× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $154.2M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $138.2M | $311.2M |
| 自由现金流率自由现金流/营收 | 6.2% | 21.9% |
| 资本支出强度资本支出/营收 | 0.7% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.24× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $634.3M | $1.8B |
8季度趋势，按日历期对齐
经营现金流CACIRMD
| Q4 25 | $154.2M | $339.7M | ||
| Q3 25 | $171.1M | $457.3M | ||
| Q2 25 | $156.0M | $538.8M | ||
| Q1 25 | $230.3M | $578.7M | ||
| Q4 24 | $126.0M | $308.6M | ||
| Q3 24 | $34.7M | $325.5M | ||
| Q2 24 | $157.2M | $440.1M | ||
| Q1 24 | $198.3M | $402.0M |
自由现金流CACIRMD
| Q4 25 | $138.2M | $311.2M | ||
| Q3 25 | $154.1M | $414.4M | ||
| Q2 25 | $128.0M | $508.2M | ||
| Q1 25 | $214.1M | $557.9M | ||
| Q4 24 | $116.1M | $288.0M | ||
| Q3 24 | $23.2M | $307.7M | ||
| Q2 24 | $134.6M | $415.2M | ||
| Q1 24 | $186.6M | $380.8M |
自由现金流率CACIRMD
| Q4 25 | 6.2% | 21.9% | ||
| Q3 25 | 6.7% | 31.0% | ||
| Q2 25 | 5.6% | 37.7% | ||
| Q1 25 | 9.9% | 43.2% | ||
| Q4 24 | 5.5% | 22.5% | ||
| Q3 24 | 1.1% | 25.1% | ||
| Q2 24 | 6.6% | 33.9% | ||
| Q1 24 | 9.6% | 31.8% |
资本支出强度CACIRMD
| Q4 25 | 0.7% | 2.0% | ||
| Q3 25 | 0.7% | 3.2% | ||
| Q2 25 | 1.2% | 2.3% | ||
| Q1 25 | 0.7% | 1.6% | ||
| Q4 24 | 0.5% | 1.6% | ||
| Q3 24 | 0.6% | 1.5% | ||
| Q2 24 | 1.1% | 2.0% | ||
| Q1 24 | 0.6% | 1.8% |
现金转化率CACIRMD
| Q4 25 | 1.24× | 0.87× | ||
| Q3 25 | 1.37× | 1.31× | ||
| Q2 25 | 0.99× | 1.42× | ||
| Q1 25 | 2.06× | 1.59× | ||
| Q4 24 | 1.15× | 0.90× | ||
| Q3 24 | 0.29× | 1.05× | ||
| Q2 24 | 1.17× | 1.51× | ||
| Q1 24 | 1.72× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CACI
| Service Other | $876.3M | 39% |
| Intelligence Community | $539.0M | 24% |
| Federal Civilian Agencies | $438.6M | 20% |
| Subcontractor | $202.5M | 9% |
| Other | $148.5M | 7% |
| Commercial And Other | $15.2M | 1% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
